<DOC>
	<DOCNO>NCT00488631</DOCNO>
	<brief_summary>The purpose study assess safety efficacy golimumab administer subcutaneously ( skin ) injection maintenance therapy .</brief_summary>
	<brief_title>An Efficacy Safety Study Golimumab ( CNTO 148 ) Participants With Moderately Severely Active Ulcerative Colitis</brief_title>
	<detailed_description>This Phase 3 , multicenter ( conduct one center ) , placebo-controlled ( inactive substance compare drug test whether drug real effect clinical trial ) , double-blind ( neither Physician participant know study medication ) , parallel-group ( medical research study compare response 2 group participant receive different intervention ) , randomized-withdrawal study . Participants clinical response golimumab Week 6 induction study C0524T16 ( NCT00488774 ) C0524T17 ( NCT00487539 ) randomly assign 1:1:1 ratio Week 0 study receive 1 follow maintenance treatment regimen administer subcutaneously every 4 week Week 52 : placebo , golimumab 50 mg , golimumab 100 mg . Participants clinical response placebo participant clinical response golimumab placebo Week 6 induction study C0524T16 ( NCT00488774 ) C0524T17 ( NCT00487539 ) randomly assign eligible enrol study ( i.e. , nonrandomized group ) receive follow treatment regimen : placebo , golimumab 100 mg golimumab 100 mg . Dose adjustment do participant clinical response golimumab placebo induction study C0524T16 ( NCT00488774 ) C0524T17 ( NCT00487539 ) lose clinical response maintenance study C0524T18 ( NCT00488631 ) . On complete study , participant opportunity continue receive study medication study extension last approximately 3 year . Efficacy primarily evaluate assess clinical response use Mayo Score . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants receive study agent administration complete Week 6 Mayo score evaluation induction study C0524T16 ( NCT00488774 ) C0524T17 ( NCT00487539 ) Participants complete Week 0 visit maintenance study C0524T18 ( NCT00488631 ) day Week 6 visit induction study C0524T16 ( NCT00488774 ) C0524T17 ( NCT00487539 ) Participants increase dose concomitant ( give time ) UC medication since Week 0 induction study C0524T16 ( NCT00488774 ) C0524T17 ( NCT00487539 ) Participants initiate concomitant UC medication since Week 0 induction study C0524T16 ( NCT00488774 ) C0524T17 ( NCT00487539 ) Participants partial total colectomy ( surgery remove part colon ) ostomy ( surgical construction artificial opening ( stoma ) external fistulization duct vessel insertion tube without supportive stent ) since Week 0 induction study C0524T16 ( NCT00488774 ) C0524T17 ( NCT00487539 ) Participants sign symptom latent active granulomatous infection ( include TB ) ; nontuberculous mycobacterial infection opportunistic infection ; infection HIV ( Human Immunodeficiency Virus ) , hepatitis B , hepatitis C Participants sign symptom malignancy suggestive possible lymphoproliferative disease ( disorder characterize proliferation lymphoid tissue , general unspecified )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Colitis , Ulcerative</keyword>
	<keyword>Golimumab</keyword>
	<keyword>CNTO 148</keyword>
</DOC>